NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
ChartMill assigns a Buy % Consensus number of 73% to NVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 108.69. This target is 10.51% above the current price.
NVS was analyzed by 31 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about NVS.
In the previous month the buy percentage consensus was at a similar level.
NVS was analyzed by 31 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-24 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-02-23 | BMO Capital | Initiate | Market Perform |
| 2024-01-23 | Morgan Stanley | Initiate | Equal-Weight |
| 2023-09-25 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2022-05-09 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2021-12-06 | Exane BNP Paribas | Downgrade | Outperform -> Neutral |
| 2021-12-03 | Bryan Garnier | Downgrade | Buy -> Neutral |
| 2021-09-20 | Deutsche Bank | Downgrade | Hold -> Sell |